ArticleCureus2025
Statin-Associated Immune-Mediated Necrotizing Myopathy With Dual Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme A Reductase (Anti-HMGCR) and Anti-OJ Positivity: A Case Report of Fulminant Weakness and Respiratory Failure.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune-mediated necrotizing myopathy (IMNM) is a rare and aggressive form of idiopathic inflammatory myopathy, which is often associated with statin exposure and myositis-specific antibodies such as anti-HMGCR or anti-synthetase antibodies. It is characterized by rapidly progressive muscle weakness, markedly elevated creatine kinase (CK), and often significant morbidity due to respiratory or bulbar involvement. We share the story of a 71-year-old man with type 2 diabetes mellitus, asthma, chronic kidney disease, and hypercholesterolemia who presented with progressive weight loss and difficulty in walking. He was on Atorvastatin for elevated cholesterol levels. His condition rapidly worsened, leading to lower limb weakness, dysphagia, and recurrent type 2 respiratory failure, requiring prolonged non-invasive ventilation. Electromyography, lower limb MRI, showed features of polymyositis, and biopsy confirmed IMNM. Serology was positive for anti-HMG-CoA (3-hydroxy-3-methylglutaryl-coenzyme A) reductase and anti-OJ antibodies. He was treated with high-dose corticosteroids, mycophenolate, and intravenous immunoglobulin. His hospital course was complicated by aspiration pneumonia, paroxysmal atrial fibrillation, and severe dysphagia requiring gastrostomy feeding. With intensive multidisciplinary care, including respiratory, rheumatology, physiotherapy, and speech therapy, he gradually improved in respiratory function and mobility, regaining upper limb strength and partial independence at discharge. This case demonstrates the diagnostic complexity of IMNM, the need for early recognition in patients with statin exposure and rapidly progressive weakness, and the importance of aggressive immunosuppression alongside comprehensive multidisciplinary care. Despite multiple complications, meaningful functional recovery is possible with timely and coordinated management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.